Results indicate that EZH2 inhibitors, especially EPZ6438, have therapeutic potential by inhibiting tumour cells’ growth whilst enhancing treatment sensitivity on HPV+ cells, inducing apoptosis and cell cycle arrest at G0/G1 phase, reducing cell migration, downregulating HPV oncogenes and epigenetic markers, and upregulating tumour suppressors and epithelial markers. Here, EZH2 is linked to neoplasm.